Original ArticleEvaluation of SARS-CoV-2 in Tears of Patients with Moderate to Severe COVID-19
Section snippets
Methods
A cross-sectional study was conducted from May 22 through June 4, 2020, in Lok Nayak Hospital, New Delhi, India, one of the largest, tertiary, COVID-19–dedicated hospitals in North India. After obtaining the Maulana Azad Medical College institutional ethics committee clearance, the trial was registered (identifier, CTRI/2020/05/025291). Adult patients with moderate and severe laboratory-confirmed COVID-19 with positive results from naso-oropharyngeal RT-PCR analysis, performed 1 day before, who
Results
Of the 78 patients enrolled in the study, only 75 were considered for analysis because samples from 3 patients were found to be inadequate for analysis (Table 1). Thirty-six of the patients (48%) had moderate disease, whereas 39 patients (52%) had severe COVID-19. The cohort comprised 41 men (54.7%) and 34 women (45.3%) ranging in age from 18 to 81 years. Fifty-six patients (74.7%) had an associated systemic comorbidity. The various comorbidities included hypertension (42%), diabetes mellitus
Discussion
The role of the ocular surface as a possible portal of entry, reservoir for replication, and transmission of SARS-CoV-2 RNA has been explored extensively.9,23, 24, 25 Differences in detection of viral RNA in tears have ranged from 0% to 7%, with some researchers claiming minimal viral shedding in ocular secretions.13, 14, 15, 16, 17, 18, 19 Recently, live virus has been demonstrated in ocular fluids by demonstrating cytopathic effect in Vero E6 cells.26 Although initial reports included
References (30)
- et al.
Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients
Ophthalmology
(2020) - et al.
Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?
Lancet Gastroenterol Hepatol
(2020) - et al.
Structural and functional basis of SARS-CoV-2 entry by using human ACE2
Cell
(2020) - et al.
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
Cell
(2020) - et al.
ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection
Ocul Surf
(2020) - et al.
Ocular findings and proportion with conjunctival SARS-COV-2 in COVID-19 patients
Ophthalmology
(2020) - et al.
2019-nCoV transmission through the ocular surface must not be ignored
Lancet
(2020) - et al.
The evidence of SARS-CoV-2 infection on ocular surface
Ocul Surf
(2020) - et al.
Keratoconjunctivitis as the initial medical presentation of the novel coronavirus disease 2019 (COVID-19)
Can J Ophthalmol
(2020) - et al.
Ocular manifestation as first sign of coronavirus disease 2019 (COVID-19): interest of telemedicine during the pandemic context
J Fr Ophthalmol
(2020)
Coronavirus diversity, phylogeny and interspecies jumping
Exp Biol Med
There may be virus in conjunctival secretion of patients with COVID-19
Acta Ophthalmol
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Nature
Structural basis of receptor recognition by SARS-CoV-2
Nature
COVID-19: limiting the risks for eye care professionals
Ocul Immunol Inflamm
Cited by (82)
Detection of anti-SARS-CoV-2 antibodies in tears: Ocular surface immunity to COVID-19
2023, Archivos de la Sociedad Espanola de OftalmologiaConjunctival conveyance of SARS-CoV-2 in asymptomatic and non-severe symptomatic COVID-19 patients
2023, Journal Francais d'OphtalmologieThe renin-angiotensin system in the eye
2023, Angiotensin: From the Kidney to CoronavirusOutpatient human coronavirus associated conjunctivitis in India
2022, Journal of Clinical VirologyNoninvasive Visualization of the Tear Film Microaerosol During Noncontact Tonometry Measurements
2022, American Journal of Ophthalmology
Supplemental material available at www.aaojournal.org.
Disclosure(s): All authors have completed and submitted the ICMJE disclosures form. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
HUMAN SUBJECTS: Human subjects were included in this study. After obtaining the institutional ethics committee clearance at Maulana Azad Medical College, the trial was registered (CTRI/2020/05/025291). In accordance with the Declaration of Helsinki, written informed consent was obtained from all the patients.
No animal subjects were included in this study.
Author Contributions:
Conception and design: Arora, Goel
Analysis and interpretation: Arora, Goel, Saxena, Manchanda
Data collection: Arora, Goel, Kumar, Chhabra, Saxena, Manchanda, Pumma
Obtained funding: N/A; Study was performed as part of the authors' regular employment duties. No additional funding was provided.
Overall responsibility: Arora, Goel